Navigation Links
Mentice AB Announces the Appointment of Lars Lonn as Clinical Director for Mentice
Date:3/28/2008

GOTHENBURG, Sweden, March 28 /PRNewswire/ -- Mentice AB, a leading supplier of virtual reality based training applications within the field of medicine has recently appointed Lars Lonn as Clinical Director for Mentice.

Professor Lonn, an Interventional Radiologist, is also a leading European professor within the field of Endovascular Surgery and a faculty member of Rigshospital Health Sciences in Copenhagen, Denmark.

Professor Lonn recently completed a study with Max Berry, MD, Mikael Hellstrom, MD, Jan Gothlin, MD, and Richard Reznick, MD, MEd, FRCSC, which was featured in the Journal of Vascular Interventional Radiology entitled, "Endovascular Training with Animals versus Virtual Reality Systems: An Economic Analysis."

Goran Malmberg, CEO and President of Mentice said, "This is a monumental step forward for us. Professor Lonn will have a vital role with Mentice verifying the direction of our product development, while increasing the awareness and need for training solutions in healthcare. In the long run, we feel that Clinical Directors will play a vital role in driving medical training through the use of medical simulation."

About Mentice:

Mentice is a leader in medical simulation with approximately 600 installations worldwide, 100 validation studies and more than 30 issued and pending patents. Mentice's Family of Procedicus (TM) simulators focus on the area of minimally invasive surgery within the fields of endovascular intervention, core skills training, laparoscopy and arthroscopy training.

Website info: http://www.mentice.com

For more information contact: Goran Malmberg at +46 31 33 99 401 (Gothenburg office) or email, goran.malmberg@mentice.com.

Release #32808


'/>"/>
SOURCE Mentice Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Mentice AB Announces Leadership Changes Within Its Worldwide Operations
2. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
3. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
4. Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering
5. BioLife Solutions Announces Exclusive CryoStor(TM) Supply Agreement With the New England Cryogenic Center, Inc.
6. Carrington Announces Nasdaq Communication; Prepares for Shares to Be Quoted on the OTC Bulletin Board and Pink Sheets
7. China Kangtai Cactus Biotech Files 2nd Quarter 2007 10QSB and Announces Unaudited Quarterly Results
8. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
9. Advanced Life Sciences Announces Receipt of Nasdaq Staff Letter
10. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
11. Angiotech announces additional diameters of sutures to further expand its Quill(TM) SRS PDO product line
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/20/2017)... TX (PRWEB) , ... September ... ... LLC (IPS), a leading global provider of engineering, architecture, project controls, construction ... of prefabricated cleanrooms, today announced the unveiling of the iCON™ brand which ...
(Date:9/20/2017)... ... September 20, 2017 , ... Foresight Institute, a leading ... transformative technologies, announced the winners for the 2017 Foresight Institute Feynman Prizes.These are ... nanotechnology/molecular manufacturing. , Established in 1993 and named in honor of pioneer physicist ...
(Date:9/19/2017)... , ... September 19, 2017 , ... ... largest group of funded early-stage tech companies. “Grit” author Angela Duckworth and her ... joining the ic@3401 community is Cooley, an international law firm with decades of ...
(Date:9/19/2017)... 19, 2017 ValGenesis Inc., the global leader ... to announce the strategic partnership with VTI Life Sciences ... validation services using the latest technology available in the ... clients with efficient and cost-effective validation services using ValGenesis ... the ValGenesis VLMS system. ...
Breaking Biology Technology:
(Date:4/13/2017)... According to a new market research report "Consumer IAM Market ... Authorization), Service, Authentication Type, Deployment Mode, Vertical, and Region - Global Forecast ... from USD 14.30 Billion in 2017 to USD 31.75 Billion by 2022, ... ... MarketsandMarkets Logo ...
(Date:4/6/2017)... LONDON , April 6, 2017 ... Control, RFID, ANPR, Document Readers, by End-Use (Transportation & ... Energy Facility, Oil, Gas & Fossil Generation Facility, Nuclear ... Healthcare, Educational, Other) Are you looking for ... Authentication sector? ...
(Date:4/3/2017)...  Data captured by IsoCode, IsoPlexis Corporation,s ... statistically significant association between the potency of ... objective response of cancer patients post-treatment. The ... cancer patients will respond to CAR-T cell ... to improve both pre-infusion potency testing and cell ...
Breaking Biology News(10 mins):